Acquired resistance to EGFR-targeted therapies in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic colorectal cancer (mCRC) treatment often involves anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies like cetuximab and panitumumab.
• Intrinsic resistance, such as RAS mutations, and acquired resistance limit the clinical efficacy of these targeted therapies.
• Acquired resistance typically develops within 3-12 months, necessitating an understanding of underlying molecular mechanisms.

Purpose of the Study:

• To investigate the molecular alterations driving acquired resistance to anti-EGFR therapies in metastatic colorectal cancer.
• To identify key signaling pathways involved in tumor cell escape from anti-EGFR blockade.
• To evaluate the utility of circulating tumor DNA (ctDNA) and patient-derived xenografts (PDXs) in monitoring resistance and testing novel therapeutic strategies.

Main Methods:

• Analysis of molecular profiling data from clinical specimens.
• Preclinical modeling using cell lines and patient-derived xenografts.
• Examination of genetic alterations in the EGFR-RAS-RAF-MEK signaling pathway and receptor tyrosine kinases.
• Monitoring of resistance mechanisms using circulating tumor DNA.

Main Results:

• Genetic alterations in the EGFR-RAS-RAF-MEK pathway and receptor tyrosine kinases were identified as key mechanisms of acquired resistance.
• Tumor cells escape anti-EGFR blockade through the reactivation of MEK-ERK or AKT signaling pathways.
• Circulating tumor DNA and PDXs demonstrated utility in tracking resistance development and evaluating combination therapies.

Conclusions:

• Understanding acquired resistance mechanisms is crucial for improving anti-EGFR therapy outcomes in mCRC.
• Targeting reactivated signaling pathways (MEK-ERK, AKT) offers potential strategies to overcome resistance.
• ctDNA and PDXs are valuable tools for personalized monitoring and therapeutic development in anti-EGFR resistant mCRC.